DOCSLIB.ORG

The Leading Life Sciences Clusters in Europe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Leading Life Sciences Clusters in Europe The leading life sciences clusters in Europe September 2015 A study commissioned by: Map of the Clusters Oslo Stockolm - Uppsala Medicon Valley Scotland Ireland North-West England The Netherlands Berlin – Brandenburg London Cambridge Oxford Flanders Heidelberg - Rhine-Neckar Vienna BioValley Île-de-France Munich-Bavaria Zurich Rhône-Alpes 2 - SCIENCE I BUSINESS Foreword Europe is lauded for the quality of its science, but there To define the most innovative life sciences clusters, key are also well-signposted shortcomings in the systems for quantitative criteria were analysed. These include the commercialising this research. percentage of GDP allocated to R&D, the number of life science companies and their turnover, the number The comparison of life sciences clusters across Europe is of researchers, the level of education, the number of a way not only to track down excellent science, but also teaching hospitals, the number of patents, and so on. to assess the relative strengths of different regions when it comes to engaging with industry and supporting These quantitative measures say something of course, innovation. However, it is also a complex task. but they do not read across directly to a qualitative assessment. To put flesh on these numbers, the study Clusters can be formed at a variety of levels: they can be considered the reputation of local universities, the concentrated in a city, they can spread across borders, academic excellence, the capacity to absorb EU funding, they can be the result of a national strategy to boost the quality of the R&D infrastructure and support innovation. It is also the case that depending on their services and the ease of doing business. It also looked at audience, clusters may like to present themselves as policy measures, such as public investment policies and independent clusters in their own right, or on other tax incentives. In other words all the reasons why one occasions to be seen as part of a larger entity. In the cluster or another could be a source of innovation for a UK, for example, Cambridge is promoted both as the large science-driven company such as Sanofi — and the area around the city and also as part of the ‘Golden ease with which this innovation can be tapped. Triangle’ of Cambridge, Oxford and London. Nodding to the American view of geography, the UK BioIndustry To complement the analysis, some key figures in Association recently began referring to ‘The UK the clusters were interviewed to give their personal Cluster’. perspective on the strengths and weaknesses of the clusters. France is a champion in multiplying its innovation nodes. Areas covered by umbrella organisations such as This study offers an overview of the leading life sciences Lyonbiopole or Medicen, which are defined as clusters, innovation hubs across Europe – some of which are contain within them multiple sub-groups, labelled as also world leaders. It can form the basis for setting out “clusters” by the French state. The city of Oslo counts no a strategy for systematic engagement with Europe’s less than 11 life sciences clusters. leading scientists, to enrich discovery research and generate innovation. Juggling with this diversity of definitions, this study, commissioned by Sanofi, covers 17 geographical areas Maryline Fiaschi that fit a common preliminary criterion: that they Director, Science|Business form a coherent structure where universities, research labs, science parks, incubators, hospitals, start-ups, large companies and government agencies cooperate, with the joint aim of generating innovation. They also respond to a national, regional or local strategy to join forces with the objective of strengthening the area’s competitiveness and economic growth. 3 - SCIENCE I BUSINESS Table of Contents Map of the clusters 2 Europe’s leading life sciences clusters Vienna 5 Flanders 7 Medicon Valley 9 Île-de-France 11 Rhône-Alpes 13 Berlin – Brandenburg 15 Heidelberg - Rhine-Neckar 17 Munich – Bavaria 19 Ireland 21 Oslo 23 Stockholm-Uppsala 25 BioValley 27 Zurich 29 The Netherlands 31 London – Cambridge – Oxford 33 North-West England 35 Scotland 37 References and credits 39 4 - SCIENCE I BUSINESS Vienna Facts and figures Areas of excellence % of GDP allocated to R&D 2.84% (Austria 2013) > Medical biotechnology Total private R&D investment €1.51 billion (2011) > Anti-infectives Total public R&D investment €242.924 million (2011) > Immunology Economic growth 0.3% (2012) > Oncology Total annual turnover for the life sciences sector €9.089 billion (2013) > Respiratory diseases Life sciences companies 378 (2012) > Medical technology (in particular Number of employees 21,031 (2012) electromechanical medical Students with tertiary education 150,000 (38,290 in life devices and software for medicine, sciences) (2012) telemedicine and e-health) Number of researchers 40,398, including 7,744 in life sciences (2014) Number of scientific publications 8,030 (2013-2014) university business incubators, have Total citations (2013-2014) 19,256 helped to pull in private investors and Geographical coverage of the cluster 415 km² fostered cooperation with multinational companies. Cluster overview employ 14,289, staff of whom 7,744 are The Vienna region has 25 research researchers. As one demonstration of the Business and investment institutions and five universities, with quality of the research, LISAvienna cites Vienna is home to 378 biotech, pharma more than 38,290 life sciences students. 5,733 papers published in international and medical technology companies, The cluster is concentrated within the city journals in 2013. In 2012, researchers in which in 2012 employed 21,031 people. of Vienna which covers approximately the region filed 42 life science patents, The cluster has the attraction of being 415 km2 on both banks of the Danube. while the active portfolio totals 745 close to growing markets in Eastern Inward investment and development of patents. A total of 22 products discovered Europe. The corporation tax rate is the cluster is supported by LISAvienna, in the region are in clinical trials. 25 per cent and there is the option of a body that is jointly funded by the national government and the City of R&D infrastructures and Universities: Vienna. In the past 15 years, the Austrian • University of Natural Resources and government has invested over €400 support services Life Sciences million in R&D infrastructure in Vienna. Vienna has particular strengths in • Medical University of Vienna In 2013, the total annual turnover for the anti-infectives, immunology, oncology, • University of Veterinary Medicine life sciences sector in the region was €9.09 respiratory diseases and medical Vienna billion. Multinationals including Baxter, technology. Since 1998, the Austrian • University of Vienna Boehringer Ingelheim, Eli Lilly, Novartis national funding bank, Austria • Vienna University of Technology and Sandoz have made investments here, Wirtschafts service, has awarded and are working with small companies, roughly €206 million in grants, loans Academic institutes – Applied universities and research centres. and guarantees to life science companies Universities: in Vienna. In the same period, the • University of Applied Sciences FH Technology Agency of the City of Vienna, Campus Vienna Academic excellence the Vienna Science and Technology • University of Applied Sciences In the 2014 Shanghai Ranking, the Fund and the Vienna Business Agency Technikum Vienna University of Vienna ranks in the top 200 have invested €190 million in life science while the Medical University of Vienna projects and infrastructure. These and Other academic institutes: ranks among the top 300 universities. other funding agencies, such as Austrian • Austrian Centre of Industrial Vienna’s 25 research institutions Research Promotion Agency (FFG) and Biotechnology 5 - SCIENCE I BUSINESS The European Research Council (ERC) has awarded a series of grants to Vienna-based life sciences researchers - Medical University • Alwin Kohler, of the Medical of Vienna University of Vienna, was awarded - LISAvienna €1.48 million for “Nuclearpore - Campus Vienna Biocentre connection: adaptor complexes bridging genome regulation”. • Wulf Eckhard Haubensak, of the Vienna Research Institute of Molecular Pathology, was awarded €1.5 million Austria for “Circuit mechanics of emotions in the limbic system”. • Daniel Wolfram Gerlich, of the Campus Vienna Biocentre Institute of Molecular Biotechnology, The Campus Vienna BioCentre is home to a number of laboratories, several was awarded €1.5 million for internationally successful biotech companies and recent start-ups. Services “Bridging spatial and temporal available on the campus include the Campus Science Support Facilities, which resolution gaps in the study of cell provides access to a range of new technologies. division”. • Barbara Greineder, of the University LifeScience Vienna Muthgasse of Veterinary Medicine, was awarded LifeScience Vienna Muthgasse is the newest life science park in Vienna. It brings €1.23 million for the “Evolution of together university and research institutions, including the University of Natural sensory organ morphology: Genetic Resources and Life Sciences and the Austrian Institute of Technology, with a analysis of eye size”. number of life science companies and organisations. The first phase, ‘Biotech I’ with more than 24,000 square metres is already in use. The next building, ‘Biotech II’ will provide 29,000 square metres of office and lab space. group taxation, allowing international companies
Load more

Recommended publications
  • 2016-17 Department: UCL Medical School Faculty: Medical Sciences CONNECTED CURRICULUM
    UCL QUALITY REVIEW FRAMEWORK - ANNEX 6.1.3: ASER DEVELOPMENT & ENHANCEMENT PLAN Academic Session: 2016-17 Department: UCL Medical School Faculty: Medical Sciences CONNECTED CURRICULUM Last session, Departments were invited to discuss how they intended to begin their preliminary assessment of their taught provision by benchmarking each programme against the grid in the Connected Curriculum Enhancement Guide. Programmes were asked to evaluate and clearly state where the programme or cluster of similar programmes was benchmarked in relation to each dimension of the Connected Curriculum. In this section, Departments are asked to indicate the extent to which their programme(s) reflect each of the six dimensions, to highlight notable examples of good practice, and (in the Development and Enhancement plan below) to list up to six actions that the department/programme team will now take to enhance the programme(s) over the next two to three years. Departments will then be asked to review progress in relation to these actions in the Autumn 2019 ASER. The broad evaluation of the programme(s) as ‘Beginning’, ‘Developing’, ‘Developed’ or ‘Outstanding’ for each dimension will enable the Department/Programme Leader to track progress in relation to all six dimensions over time. It is intended to be a broadly agreed description of current practice in the programme(s) as a whole. General guidance on interpreting these terms is found on p6-7 of the Connected Curriculum online guide: https://www.ucl.ac.uk/teaching-learning/sites/teaching-learning/files/connected_curriculum_brochure_21_june_2017.pdf Departments may also find the ‘Twenty Questions’ on p10 helpful. If you have a large number of UG programmes in your department, a suggested approach is to use this form to provide a departmental summary of your programmes and then to identify those particular programmes which are excelling or which need more development by completing a form with a summary for each programme (or cluster of very similar programmes).
    [Show full text]
  • Projects Nominated in 2020 UCL Provosts Public Engagement
    Projects Nominated in 2020 UCL Provost's Public Engagement Awards Lead UCL Lead external Project Name UCL Department External Organisation Contact Contact A strengths-based approach to autism and employment: Insights, experiences, and Psychology and Human Development, UCL Anna Melissa best practice strategies from the Deutsche Bank UK autistic graduate internship Institute of Education – Centre for Research in Alex Wilson Deutsche Bank Romualdez programme Autism and Education Addressing Infrastructural Vulnerabilities: a participatory spatial intervention in the Andrea Rigon Development Planning Unit Joana Dabaj CatalyticAction refugee-hosting town of Bar Elias, Lebanon Evangelos Beatboxing After Laryngectomy UCL Institute of Education, Department of CCM Thomas Moors Shout at Cancer Himonides Education, Practice and Society, Institute of Building the evidence base for effective policy: the role of education in international Moses Oketch Education, Centre for Education and International Jess Atkinson Department for International Development (DFID) development Development (CEID) Ameenat Lola Childhood rare eyes disease: patient and public involvement and engagement UCL GOS Institute of Child Health Deirdre Leyden GOSH Patient and Public Involvement in Research Lead Solebo Civic Design CPD and Knowledge Exchange: Co-designing Neighbourhoods with Pablo Sendra The Bartlett School of Planning Leslie Barson Granville Community Kitchen Communities Collaborative City Planning Strategies Masters Module BPLN0033 Elena Besussi Bartlett School of
    [Show full text]
  • Review of UCL Medical School
    London regional review 2012–13 Review of UCL Medical School This visit is part of a regional review and uses a risk-based approach. For more information on this approach see http://www.gmc- uk.org/education/13707.asp. Review at a glance About the School Programme MBBS University UCL Medical School Years of course 6 Programme structure Year 1 – Fundamentals of clinical science 1 Year 2 – Fundamentals of clinical science 2 Year 3 – Scientific method in depth (iBSc) Year 4 – Integrated clinical care Year 5 – Life cycle Year 6 – Preparation for practice Number of students 1,969 (2011 MSAR) Number of LEPs UCL reported 196 clinical placements across 28 trusts or other providers, excluding GP placements. Local deanery London Deanery Last GMC visit 2004-5 QABME Outstanding actions None from last visit 1 About the visit Visit dates 22-23 November 2012 Sites visited UCL Medical School Areas of exploration MBBS Were any patient No safety concerns identified during the visit? Were any significant No educational concerns identified? Has further regulatory No action been requested via the responses to concerns element of the QIF? Summary 1 London has been chosen as the region for review in 2012-13 and all five London medical schools have been visited as part of this review. The north central regional visit team visited UCL Medical School (the School), a Division in the Faculty of Medical Sciences, University College London, in November 2012. 2 UCL is the third largest medical school in London with 1,969 students. The School has three main clinical campuses: Bloomsbury, the Royal Free and the Whittington.
    [Show full text]
  • London: an Innovation Hub for Health & Life Sciences Through
    LONDON: AN INNOVATION HUB FOR HEALTH & LIFE SCIENCES THROUGH THE APPLICATION OF DATA AND AI SUPPORTED BY Next page Access the market: 19 from NHS to Biopharma CONTENTS Foreword 3 The NHS adoption of AI technologies 20 This is an interactive guide, London’s key strengths 4 l Spotlight on UCLPartners 21 so click on the title to jump to any section. An Innovative Biopharma Cluster 22 An ecosystem built for growth 5 l Case study - MultiplAI 23 Access to funding 6 Government support 7 An accessible, diverse 24 l Case study - Kheiron Medical 9 and data-rich environment Diverse population and data 24 London’s life sciences clusters 10 Partner with the Health Data 25 The Knowledge Quarter 11 Research Hubs Whitechapel: Barts Life Sciences Hub 12 l Spotlight on DATA-CAN HDR 26 White City Innovation District 13 Southbank to Sutton 14 London’s resilient COVID-19 response 27 l Case study - InstaDeep 28 Talent and educational excellence 15 Existing talent 16 How can we help 29 The next generation 17 How London & Partners can support 29 l Case study - PEP Health 18 How MedCity can support 29 2 Contents page FOREWORD COVID-19 has accelerated data-driven innovation across often siloed organisations. Similarly, policy is being the globe, with artificial intelligence and data science at developed to overcome legacy systems and regulations, the forefront of addressing human disease and health. which will underpin and speed up innovations. The coronavirus pandemic has led to increased acceptance of new technologies with strong buy-in from all corners Not only can bioinformatics and use of healthcare Allen Simpson Neelam Patel data lead to better health systems and outcomes, this of the life sciences and healthcare sector determined to CEO also has the potential to create many new jobs Acting CEO keep this momentum going.
    [Show full text]
  • Review 2011 1 Research
    LONDON’S GLOBAL UNIVERSITY ReviewHighlights 2011 2011 Walking on Mars © Angeliki Kapoglou Over summer 2011, UCL Communications held a The winning entry was by Angeliki Kapoglou (UCL Space photography competition, open to all students, calling for & Climate Physics), who was selected to serve as a member images that demonstrated how UCL students contribute of an international crew on the Mars Desert Research Station, to society as global citizens. The term ‘education for global which simulates the Mars environment in the Utah desert. citizenship’ encapsulates all that UCL does to enable Researchers at the station work to develop key knowledge students to respond to the intellectual, social and personal needed to prepare for the human exploration of Mars. challenges that they will encounter throughout their future careers and lives. The runners-up and other images of UCL life can be seen at: www.flickr.com/uclnews Contents Research 2 Follow UCL news www.ucl.ac.uk Health 5 Insights: a fortnightly email summary Global 8 of news, comment and events: www.ucl.ac.uk/news/insights Teaching & Learning 11 Events calendar: Enterprise 14 www.events.ucl.ac.uk Highlights 2011 17 Twitter: @uclnews UCL Council White Paper 2011–2021 YouTube: UCLTV Community 21 In images: www.flickr.com/uclnews Finance & Investment 25 SoundCloud: Awards & Appointments 30 www.soundcloud.com/uclsound iTunes U: People 36 http://itunes.ucl.ac.uk Leadership 37 UCL – London’s Global University Our vision Our values • An outstanding institution, recognised as one of the world’s
    [Show full text]
  • Ucl Medical School Internal Quality Review
    UCL MEDICAL SCHOOL INTERNAL QUALITY REVIEW Contents INTRODUCTION .....................................................................................................................................................4 Regulatory Framework.........................................................................................................................................4 Overview of Educational Organisational Structures ............................................................................................4 Overview of Educational Programmes.................................................................................................................5 SECTION 1. KEY DEVELOPMENTS......................................................................................................................7 1.1 Findings from previous review .......................................................................................................................7 1.2 Progress on implementation of the recommendations ................................................................................10 1.2.1 MBBS ....................................................................................................................................................10 1.2.2 Postgraduate Education ........................................................................................................................13 SECTION 2. STUDENTS, STAFF AND LEARNING RESOURCES.....................................................................15 2.1 Student Profile..............................................................................................................................................15
    [Show full text]
  • Life Sciences Sector Deal 2 Industrial Strategy Life Sciences Sector Deal 2 Foreword
    Industrial Strategy Life Sciences Sector Deal 2 Industrial Strategy Life Sciences Sector Deal 2 Foreword Last year the Life Sciences develops to encourage and spread Sector Deal set out the first these new technologies. Advanced phase of implementing the Life therapies are making precision Sciences Industrial Strategy medicines, targeted to the individual patient, a reality here in the UK. through joint commitments between the government This second Life Sciences Sector Rt Hon Greg Clark MP and the sector to invest in the Deal deepens our partnership with industry, universities and charities and United Kingdom’s life sciences Secretary of State for Business, demonstrates how the NHS is pivotal as Energy and Industrial Strategy landscape. a delivery partner. It contains significant The agreements made in the first action to address the Industrial Strategy deal capitalised on the enormous Grand Challenges and our mission to opportunities for growth that the life transform the prevention, diagnosis sciences sector presents for the UK. and treatment of chronic diseases by We are seeing a continual flow of new 2030: it will support the creation of a investments across the health tech cohort of healthy participants that will and pharmaceutical sectors since the enable research into the hidden signs deal was published, with this year’s of disease and ways of diagnosing Rt Hon Matt Hancock MP second deal seeing more life sciences diseases early when interventions Secretary of State for companies investing in the UK and and treatments can be the most Health and Social Care creating high-quality, well-paid jobs. effective. The cohort will involve the public, the research community and Life sciences is a sector that operates industry with the results benefiting at the cutting-edge of technological the whole health service – an example developments.
    [Show full text]
  • Teaching and Learning in Higher Education Ed
    Teaching and Learning in Higher Education Teaching ‘… an admirable testament to UCL’s ambition to foster innovative, evidence-based and thoughtful approaches to teaching and learning. There is much to learn from here.’— Professor Karen O’Brien, Head of the Humanities Division, University of Oxford ‘Research and teaching’ is a typical response to the question, ‘What are universities for?’ For most people, one comes to mind more quickly than the other. Most undergraduate students will think of teaching, while PhD students will think of research. University staff will have similarly varied reactions depending on their roles. Emphasis on one or the other has also changed over time according to governmental incentives and pressure. Davies and Norbert Pachler ed. Jason P. For some decades, higher education has been bringing the two closer together, to the point of them overlapping, by treating students as partners and nding ways of having them learn through undertaking research. Drawing on a range of examples from across the disciplines, this collection demonstrates how one research-rich university, University College London (UCL), has set up initiatives to raise the pro le of teaching and give it parity with research. It explains what staff and students have done to create an environment in which students can learn by discovery, through research- based education. ‘… an exemplary text of its kind, offering much to dwell on to all interested in advancing university education.’— Ronald Barnett, Emeritus Professor of Higher Education, University College London Institute of Education Dr Jason P. Davies is a Senior Teaching Fellow at the UCL Arena Centre.
    [Show full text]
  • UCL MEDICAL SCHOOL Clinical and Professional Practice, Medical Student Administration University College London JOB DESCRIPTION
    UCL MEDICAL SCHOOL Clinical and Professional Practice, Medical Student Administration University College London JOB DESCRIPTION Job Title: Clinical and Professional Practice Tutor x 6 Division: UCL Medical School Sub Department: Clinical and Professional Practice, Medical Student Administration Location: Bloomsbury, Royal Free or Whittington Campus Grade: 7 Hours: Part-time and Sessional, mainly on Thursdays and Fridays with some scope for flexibility The MBBS Clinical and Professional Practice Modules The Clinical and Professional Practice (CPP) modules make up almost 20% of the overall MBBS programme. Learning in CPP is central to understanding medicine as an integrated whole. There are 15 CPP modules, each organised over six years: Student centred learning, patient centred learning: 1. Portfolio a. Y1 online submission at end of year b. Y2 online submission at end of year c. Y4 E-portfolio d. Y5 E-portfolio and Case of the Month e. Y6 E-portfolio and Case of the Month Patient Pathways: 2. Integrated and Community Care (Y1) 3. Cardio-metabolic Medicine (Y2) 4. Cancer Medicine (Y4) 5. Person-centred (Y5) Integrated Vertical Strands: 6. Anatomy and Imaging 7. Clinical Skills and Practical Procedures 8. Pathological Sciences 9. Use of Evidence 10. Use of Medicines Overarching Themes: 11. Mental Health Page 1 of 5 12. Social Determinants of Health a. Epidemiology b. Global Health c. Medical Sociology d. Public Health 13. Ethics and Law 14. Clinical Communication 15. Professional Practice a. Professionalism b. E-health The organisation of the CPP is complex, from both an administrative and academic perspective. CPP teaching takes place both as centrally organised and ‘peel off’ activities in dedicated teaching sessions and activities fully integrated into the horizontal modules.
    [Show full text]
  • For Peer Review Only
    BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-013897 on 2 December 2016. Downloaded from “You can’t be a person and a doctor”. The work-life balance of doctors in training: a national qualitative study ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2016-013897 Article Type: Research Date Submitted by the Author: 15-Aug-2016 Complete List of Authors: Rich, Antonia; University College London Medical School, Research Department of Medical Education Viney, Rowena; University College London Medical School, Research Department of Medical Education Needleman, Sarah; University College London Medical School, Research Department of Medical Education Griffin, Ann; University College London, Medical School Woolf, Katherine; University College London, Academic Centre for Medical Education <b>Primary Subject Medical education and training Heading</b>: Secondary Subject Heading: Qualitative research QUALITATIVE RESEARCH, work-life balance, MEDICAL EDUCATION & http://bmjopen.bmj.com/ Keywords: TRAINING, women, gender, medical training on September 24, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 86 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-013897 on 2 December 2016. Downloaded from 1 2 3 4 “You can’t be a person and a doctor”. The work-life balance of 5 6 doctors in training: a national qualitative study 7 8 9 Dr Antonia Rich, Research Associate1 10 Dr Rowena Viney, Research Associate1 11 Dr Sarah Needleman, Clinical Teaching Fellow1
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2017-020930 on 7 April 2018. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 29, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2017-020930 on 7 April 2018. Downloaded from Building motivation to participate in a Quality Improvement Collaborative; a qualitative participatory evaluation Journal: BMJ Open ManuscriptFor ID peerbmjopen-2017-020930 review only Article Type: Research Date Submitted by the Author: 05-Dec-2017 Complete List of Authors: Lalani, Mirza; Primary Care and
    [Show full text]
  • Translational Research Office, UK
    Impact Objectives • Use the Therapeutic Innovation Networks (TINs) to harness the translational experience and infrastructure of UCL and its NIHR Biomedical Research Centres to provide education, support and encouragement to early career scientists to translate their novel science • Maximise University College London’s ability to quickly and efficiently translate disease-related discoveries into high-quality therapeutic interventions and tangible treatments for patients • Ensure all TINs have an industry network with the aim of using their know-how and resource to aid the development of the portfolio The innovation game Professor David Lomas discusses the Therapeutic Innovation Networks (TINs), which are facilitating and accelerating enterprise at University College London (UCL), UK Can you begin by commercialising biomedical therapies. These of our national and international standing. introducing yourself? forums are also used to discuss barriers and For example, we have used the TINs to hurdles, and approaches to overcome them. assess our strengths and weaknesses in cell, I am Vice-Provost The Cell, Gene & Regenerative Medicine gene and regenerative therapies, and work (Health) at UCL, Head TIN has been very effective in pulling out how we can collaborate effectively with of the School of Life & the community together and articulating industry and our London partners: King’s Medical Sciences and our strengths in this area. UCL has more College London, Imperial College London Head of the UCL Medical School. I also serve research and clinical activity in the area of cell and Queen Mary University of London. This as the Academic Director of UCL Partners’ and gene therapy than any other university allows for economy of scale, more rapid Academic Health Science Centre and as a in the UK and, indeed, has a clinical portfolio translation and more effective competition Director of The Francis Crick Institute, Africa of comparable size to that of the whole of for research and enterprise income, Health Research Institute, MedCity, Non- Spain or Italy.
    [Show full text]